Entries by Max

Bipolar Androgen Therapy (BAT) State of the Art Explained by Dr. Antonarakis

/in /by

Bipolar androgen therapy (BAT) is a paradoxical treatment strategy for metastatic androgen pathway modulation–resistant prostate cancer (mAPMR), formerly known as metastatic castration‑resistant prostate cancer (mCRPC), that replaces continuous androgen suppression with cyclical, supraphysiologic testosterone exposure, aiming to exploit the tumor’s dependence on an overactive androgen receptor (AR). The approach was pioneered by Samuel Denmeade and […]

Newsletter 32/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Research seems to have slowed down for August, but what we have this week is really good. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find […]

Soon to Be Phase 1/2 Trial: Bria-PROS+ Receives FDA Clearance to Begin Clinical Study in Prostate Cancer

/in , , , /by

Bria-PROS+ has received clearance from the U.S. Food and Drug Administration to enter clinical testing as an investigational personalized, off-the-shelf cellular immunotherapy for prostate cancer. The FDA completed its review of the Investigational New Drug application allowing a Phase 1/2a clinical study to move forward. The study is expected to evaluate the safety, tolerability, and […]

UPDATE: Seven Complete Responses in a 19-Patient Cohort of 67Cu-SAR-bisPSMA Trial for mCRPC

/in , , , /by

A small but encouraging clinical dataset suggests that 67Cu-SAR-bisPSMA may produce substantial anti-tumour activity in patients with metastatic castration-resistant prostate cancer (mCRPC) who have exhausted multiple treatment options. The findings come from the SECuRE clinical trial, in which 19 participants received treatment with 67Cu-SAR-bisPSMA at an 8 GBq dose. Despite the advanced disease setting, treatment […]

B7-H3: A Continuum-Wide, AR-Repressed Anchor for Combinatorial Prostate Cancer Therapy

/in /by

A landmark 2026 study in Clinical Cancer Research reframes surface-target therapy in advanced prostate cancer by placing B7-H3 (CD276) at the center of a continuum-wide strategy. Integrating the JHU-PANORAMA single-cell atlas (~1M cells, 213 patients) with patient-derived xenografts, metastatic rapid-autopsy tissues, and mechanistic cell-line work, the authors show that B7-H3 is the most uniformly expressed […]

Viagra Might Help To Reduce Metastasis

/in , /by

A recent study is drawing attention for a surprising reason: sildenafil, the active ingredient in Viagra, may do more than treat erectile dysfunction. Researchers reported evidence that it could also make it harder for cancer cells to spread, by interfering with the cells’ ability to access cholesterol, which appears to be important for metastasis. The […]

Blocking BCL-XL Increases ADC Effectiveness

/in , /by

UCLA researchers have reported a promising way to improve antibody-drug conjugates, or ADCs, in metastatic castration-resistant prostate cancer, a disease that remains difficult to control once it stops responding to hormone therapy. Their work suggests that pairing ADCs with a drug that blocks BCL-XL can make prostate cancer cells more vulnerable, leading to greater cell […]

Pluvicto Moves Into First-Line Metastatic Prostate Cancer, Marking Shift Toward Earlier Radioligand Therapy

/in , , , /by

A new regulatory approval is reshaping the treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC), bringing radioligand therapy into much earlier stages of disease. Pluvicto (lutetium Lu-177 vipivotide tetraxetan aka 177Lu-PSMA-617), a therapy targeting prostate-specific membrane antigen (PSMA), can now be used in combination with standard androgen deprivation therapy and androgen receptor pathway inhibitors in […]

Newsletter 31/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Another heatwave, another newsletter (but the two are not correlated!). Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. Clinical Research Phase 2 Trial […]

Phase 2 Trial for Xaluritamig in Patients With mCRPC and Suboptimal Response to Pluvicto

/in , , /by

Thomas Jefferson University is running a phase 2 study of xaluritamig, also known as AMG 509, in adults with metastatic castration-resistant prostate cancer whose disease has shown a suboptimal response to Lu-177 vipivotide tetraxetan (aka 177Lu-PSMA 617) the radioligand therapy better known as Pluvicto. The trial reflects a very specific and clinically important question: what […]